Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Jacobs, M. Deenen, M. Joerger, H. Rosing, N. Vries, D. Meulendijks, A. Cats, J. Beijnen, J. Schellens, A. Huitema (2019)
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive AnalysisCPT: Pharmacometrics & Systems Pharmacology, 8
E. Lin, Jeffrey Morris, G. Ayers (2002)
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.Oncology, 16 12 Suppl No 14
M. Deenen, H. Rosing, M. Hillebrand, J. Schellens, J. Beijnen (2013)
Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 913-914
Eduard Schmulenson, L. Krolop, S. Simons, Susanne Ringsdorf, Y. Ko, U. Jaehde (2020)
Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approachCancer Chemotherapy and Pharmacology, 86
G. Wilkes (2005)
Therapeutic options in the management of colon cancer: 2005 update.Clinical journal of oncology nursing, 9 1
(1998)
NONMEM user’s guide, part V
D. Longley, D. Harkin, P. Johnston (2003)
5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 3
M. Deenen, D. Meulendijks, H. Boot, M. Legdeur, J. Beijnen, J. Schellens, A. Cats (2015)
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junctionCancer Chemotherapy and Pharmacology, 76
Rongxin Zhang, Xiaojun Wu, D. Wan, Zhenhai Lu, Ling-heng Kong, Z. Pan, Gong Chen (2012)
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology, 23 5
E. Schindler, M. Karlsson (2017)
A Minimal Continuous-Time Markov Pharmacometric ModelThe AAPS Journal, 19
R. Gieschke, H. Burger, B. Reigner, K. Blesch, J. Steimer (2003)
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.British journal of clinical pharmacology, 55 3
Gail Wilkes, Diane Doyle (2005)
Palmar-plantar erythrodysesthesia.Clinical journal of oncology nursing, 9 1
A. Dosne, M. Bergstrand, M. Karlsson (2017)
An automated sampling importance resampling procedure for estimating parameter uncertaintyJournal of Pharmacokinetics and Pharmacodynamics, 44
R. Upton, D. Mould (2014)
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling MethodsCPT: Pharmacometrics & Systems Pharmacology, 3
J. Roosendaal, B. Jacobs, D. Pluim, H. Rosing, N. Vries, E. Werkhoven, B. Nuijen, J. Beijnen, A. Huitema, J. Schellens, S. Marchetti (2020)
Phase I pharmacological study of continuous chronomodulated capecitabine treatmentPharmaceutical Research, 37
Emilie Henin, Benoit You, E. Vancutsem, Paulo Hoff, Jim Cassidy, Chris Twelves, K. Zuideveld, Florin Sirzén, C. Dartois, Gilles Freyer, Michel Tod, Pascal Girard (2009)
A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving CapecitabineClinical Pharmacology & Therapeutics, 85
R. Team (2014)
R: A language and environment for statistical computing.MSOR connections, 1
B. Reigner, K. Blesch, E. Weidekamm (2001)
Clinical Pharmacokinetics of CapecitabineClinical Pharmacokinetics, 40
R. Keizer, Michel Benten, J. Beijnen, J. Schellens, A. Huitema (2011)
Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer methods and programs in biomedicine, 101 1
Ellen Derissen, M. Hillebrand, H. Rosing, J. Schellens, J. Beijnen (2015)
Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.Journal of pharmaceutical and biomedical analysis, 110
İ. Kara, B. Şahin, M. Erkişi (2006)
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.Breast, 15 3
G. Milano, M. Étienne-Grimaldi, M. Mari, S. Lassalle, J. Formento, M. Francoual, J. Lacour, P. Hofman (2008)
Candidate mechanisms for capecitabine-related hand-foot syndrome.British journal of clinical pharmacology, 66 1
Liping Zhang, S. Beal, L. Sheiner (2003)
Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case PerformanceJournal of Pharmacokinetics and Pharmacodynamics, 30
B. Jacobs, J. Meulenaar, H. Rosing, D. Pluim, M. Tibben, N. Vries, B. Nuijen, A. Huitema, J. Beijnen, J. Schellens, S. Marchetti (2016)
A phase 0 clinical trial of novel candidate extended-release formulations of capecitabineCancer Chemotherapy and Pharmacology, 77
L. Lindbom, J. Ribbing, E. Jonsson (2004)
Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programmingComputer methods and programs in biomedicine, 75 2
Ellen Derissen, Bart Jacobs, A. Huitema, H. Rosing, J. Schellens, J. Beijnen (2016)
Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.British journal of clinical pharmacology, 81 5
Capecitabine is an oral pro-drug of 5-fluorouracil. Patients with solid tumours who are treated with capecitabine may develop hand-and-foot syndrome (HFS) as side effect. This might be a result of accumulation of intracellular metabolites. We characterised the pharmacokinetics (PK) of 5-fluorouridine 5′-triphosphate (FUTP) in peripheral blood mononuclear cells (PBMCs) and assessed the relationship between exposure to capecitabine or its metabolites and the development of HFS. Plasma and intracellular capecitabine PK data and ordered categorical HFS data was available. A previously developed model describing the PK of capecitabine and metabolites was extended to describe the intracellular FUTP concentrations. Subsequently, a continuous-time Markov model was developed to describe the development of HFS during treatment with capecitabine. The influences of capecitabine and metabolite concentrations on the development of HFS were evaluated. The PK of intracellular FUTP was described by an one-compartment model with first-order elimination (ke,FUTP was 0.028 h−1 (95% confidence interval 0.022–0.039)) where the FUTP influx rate was proportional to the 5-FU plasma concentrations. The predicted individual intracellular FUTP concentration was identified as a significant predictor for the development and severity of HFS. Simulations demonstrated a clear exposure-response relationship. The intracellular FUTP concentrations were successfully described and a significant relationship between these intracellular concentrations and the development and severity of HFS was identified. This model can be used to simulate future dosing regimens and thereby optimise treatment with capecitabine.
"The AAPS Journal" – Springer Journals
Published: Jan 8, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.